Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer

NCT01165216 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Ipilimumab, 3 mg
DRUG: Ipilimumab, 10 mg
DRUG: Paclitaxel
DRUG: Carboplatin

Sponsor

Bristol-Myers Squibb